TRT and Hematocrit — Why Does Testosterone Raise It?
A rise in hematocrit is the best-documented side effect of testosterone therapy — it affects as many as one in four men on injections. We walk through the mechanism step by step, explain why the delivery method matters, and look at how this risk is actually managed in clinical practice.
Number of studies
3
Safety
Requires caution
Time to effects
The first measurable rises in hematocrit typically appear after several weeks to a few months of therapy; full stabilization at the new, higher equilibrium value most often occurs between month 3 and month 12 of treatment, absent any intervention.
Who it's for
Table of contents
TL;DR
A rise in hematocrit is the best-documented side effect of testosterone therapy — it affects as many as one in four men on injections. We walk through the mechanism step by step, explain why the delivery method matters, and look at how this risk is actually managed in clinical practice.
- →Understanding the mechanism helps distinguish an expected, predictable pharmacological effect from an unusual, concerning deviation that needs further workup
- →Awareness of the dose–peak–hematocrit relationship supports an informed choice of delivery form and dosing schedule from the very start of therapy, before a problem even appears
- →Early recognition of the mechanism allows for early intervention (schedule change, dose reduction) instead of waiting for a serious breach of safety thresholds
| Phenomenon | Secondary erythrocytosis (rise in hematocrit and hemoglobin) induced by testosterone |
|---|---|
| Frequency | The best-documented TRT side effect — up to ~11% at the >50% threshold, more with injectable forms |
| Level of evidence | Strong — confirmed in RCTs, meta-analyses, and large cohorts |
| Main mechanism | EPO stimulation + direct bone marrow action + drop in hepcidin |
| Highest risk | Short-acting injectable esters with high peak concentrations |
| Lowest risk | Transdermal gels and patches with a stable concentration profile |
| Time to rise | Usually visible after a few weeks, stabilizing after 3–12 months |
| Management | Dose reduction, change of delivery form, therapeutic phlebotomy, temporary pause |
Understand
Overview
Hematocrit is the percentage of red blood cells (erythrocytes) in total blood volume. In a healthy man it typically sits between 40–50%, and testosterone is one of the strongest physiological regulators of that value — one of the reasons reference ranges for a blood count run higher for men than for women. When testosterone concentration rises above physiological levels, as happens during testosterone replacement therapy (TRT), the body responds with increased red blood cell production — a phenomenon called secondary erythrocytosis, which at higher severity is also referred to as secondary polycythemia or testosterone-associated polycythemia.
This isn't a rare, marginal reaction — it's the best-documented and most predictable side effect of testosterone therapy as a whole, confirmed across dozens of clinical trials, meta-analyses, and large observational cohorts. In placebo-controlled randomized trials, the risk of developing erythrocytosis during TRT is described as up to four times higher than in the placebo group. Depending on the threshold definition and the population studied, the rate of a meaningful hematocrit rise (above 50%) reaches the low teens as a percentage of treated men, and at the most restrictive thresholds (above 54%) it drops to low single digits — but with injectable forms that produce high peak concentrations, the rate can run considerably higher than with transdermal forms.
From the patient's and physician's perspective, the key point is that this isn't a random effect or a sign of dosing error — it's a direct, predictable consequence of testosterone's pharmacological action on bone marrow and the erythropoietin axis. That's exactly why checking blood counts — specifically hematocrit and hemoglobin — is a standing, mandatory part of monitoring any testosterone therapy, not an optional add-on but a core piece of treatment safety.
This entry focuses on the mechanism: why and how testosterone raises hematocrit, what real risk follows from that, and what tools are used to manage it. Specific numerical safety thresholds and a detailed monitoring schedule are covered separately, in our related entry on safe hematocrit values during TRT.
Mechanism of action
Testosterone increases red blood cell production through two main parallel pathways that overlap and reinforce each other. The first is stimulation of erythropoietin (EPO) secretion — a hormone produced mainly by the kidneys that is the principal signal triggering erythropoiesis, the maturation of bone marrow stem cells into red blood cells. Testosterone raises EPO concentration partly by acting on hypoxia-inducible factor (HIF), a mechanism normally activated by tissue hypoxia but here "switched on" pharmacologically by the androgen itself, independent of the body's actual oxygen needs.
The second pathway is direct and EPO-independent: testosterone acts directly on erythroid progenitor cells in the bone marrow, increasing their sensitivity to erythropoietin and speeding their maturation into mature red blood cells. Androgen receptors are present on bone marrow stem cells, so this effect doesn't require the kidneys or a rise in peripheral EPO concentration — which explains why hematocrit rises in some patients even when EPO levels remain within the normal range.
A third, indirect mechanism adds to this: testosterone lowers hepcidin, a peptide hormone produced in the liver that regulates iron absorption and availability. Lower hepcidin means greater iron availability for erythropoiesis, further facilitating new red blood cell production once the marrow is already stimulated by EPO and the androgen's direct action.
The effect is clearly dose-dependent and tied to peak concentration rather than just the average testosterone level across a dosing cycle. That's why delivery methods that produce high, sharp concentration spikes — especially short-acting injectable esters given infrequently in large single doses, like enanthate or cypionate dosed every 2–3 weeks in one large shot — carry a markedly higher erythrocytosis risk than forms that give a more stable, "flatter" concentration profile, such as transdermal gels, patches, or injections given more frequently in smaller doses. Long-acting testosterone undecanoate, despite infrequent dosing, has also been linked to relatively high erythrocytosis risk in some cohort studies, suggesting that it's not just the frequency of peaks but cumulative exposure to high concentrations overall that matters.
The rise in hematocrit isn't an immediate effect — it usually becomes noticeable after a few weeks of therapy and stabilizes (if it stabilizes at all without intervention) after roughly 3–12 months, once a new "equilibrium" is reached between erythropoiesis stimulation and the natural turnover of red blood cells. That's exactly why TRT monitoring schedules call for a blood count check within the first few months of treatment, not only after a year.
Rise in testosterone concentration
TRT raises testosterone above an individual's physiological baseline, especially during the peak concentration window after an injection.
Stimulation of erythropoietin (EPO)
Testosterone increases EPO secretion by the kidneys, partly via the HIF pathway, independent of tissues' actual oxygen demand.
Direct bone marrow stimulation
Androgen receptors on erythroid progenitor cells increase their sensitivity to EPO and speed maturation into red blood cells — independent of blood EPO levels.
Drop in hepcidin and greater iron availability
Testosterone lowers hepatic hepcidin, easing the absorption and use of iron needed to produce new hemoglobin.
Rise in red cell mass and hematocrit
The sum of the above effects increases the total number and volume of red blood cells, raising hematocrit and hemoglobin on a blood count.
Rise in blood viscosity
A higher hematocrit means thicker, more viscous blood, which theoretically increases flow resistance and cardiovascular strain.
Evidence: strong — based on 3 studies in this database.
Benefits
Common myths
MythA rise in hematocrit on TRT is a sign of dosing error or an abnormal body reaction.
FactIt's a predictable, pharmacological effect of testosterone on erythropoietin and bone marrow, present in a significant share of treated men — not a sign of error, but a phenomenon that calls for routine monitoring.
MythIf hematocrit is rising, that means TRT is "working harder" and delivering better results.
FactA rise in hematocrit doesn't correlate with the strength of the therapy's desired effects (libido, energy, muscle mass) — it's a separate, independent biological mechanism that carries risk in itself, not benefit.
MythThe delivery form doesn't matter for erythrocytosis risk — only the dose counts.
FactPeak concentrations, not just the total dose, strongly influence how pronounced the effect is — which is why injections with high peaks carry markedly higher risk than transdermal forms with a stable profile, even at a comparable weekly dose.
MythRegular blood donation or phlebotomy is a safe, fully validated solution to the problem.
FactEvidence for the effectiveness and safety of routine phlebotomy in this specific context is limited — repeated blood removal can lead to iron deficiency and theoretically worsen, rather than only ease, the risk of clotting complications.
Forms & variants
TRT and Hematocrit — Why Does Testosterone Raise It? comes in several forms that differ in bioavailability and use case — the form you pick genuinely matters for how effective the supplementation is.
Short-acting injectable esters (enanthate, cypionate) in infrequent, large doses
Produce high peak concentrations right after injection, which stimulates erythropoiesis most strongly among popular TRT forms.
Best for: Requires the closest hematocrit monitoring; risk can be reduced by splitting the dose into more frequent injections
The same esters, given more often in smaller doses
Flattening the concentration curve through more frequent, smaller injections (e.g. weekly instead of every 3 weeks) lowers peak testosterone concentrations.
Best for: People prone to elevated hematocrit who want to stay on an injectable form
Testosterone undecanoate (long-acting)
Infrequent dosing (every several to a dozen-plus weeks), but some cohorts point to a relatively high cumulative erythrocytosis risk despite lacking the sharp peaks typical of shorter esters.
Best for: Requires the same monitoring rigor as other injectable forms, despite less frequent dosing
Transdermal gels and creams
A stable, relatively flat daily concentration profile without pronounced peaks — studies link these to markedly lower erythrocytosis risk than injectable forms.
Best for: People with a history of elevated hematocrit on injections, or with elevated cardiovascular risk
Transdermal patches
Similar to gels, a stable release profile, lower erythrocytosis risk than injections, though used less often due to skin irritation.
Best for: An alternative to gels for people who prefer a patch format
Practice
Frequently asked questions
Testosterone stimulates erythropoietin production in the kidneys, acts directly on erythroid progenitor cells in the bone marrow, and lowers hepcidin, increasing iron availability for erythropoiesis. These three mechanisms overlap, resulting in increased red blood cell production and a higher hematocrit.
A moderate rise falls within the expected, monitored response to therapy. A significantly elevated hematocrit increases blood viscosity and the theoretical risk of thromboembolic complications, and cohort studies link secondary polycythemia on TRT to a higher risk of major cardiovascular events in the first year of therapy — which is why it calls for regular checks and a response when it exceeds accepted thresholds.
Transdermal forms — gels and patches — give the most stable testosterone concentration profile without pronounced peaks and carry markedly lower erythrocytosis risk than injections, especially those given infrequently in large doses.
Yes — because it's mainly peak concentration, not the weekly dose itself, that drives erythropoiesis, splitting the same dose into more frequent, smaller injections flattens the concentration curve and in clinical practice often lowers hematocrit without needing to reduce the total testosterone dose.
It's one of the available options, but evidence for its long-term effectiveness and safety in this specific use is limited. Repeated blood removal can lead to iron deficiency and theoretically activate pro-thrombotic mechanisms tied to tissue hypoxia, so a decision to use it regularly is worth making together with a physician, also weighing alternatives such as dose reduction or a change of delivery form.
No. TRAVERSE showed that TRT as a whole doesn't significantly increase the risk of major cardiovascular events in appropriately selected and monitored patients, but it also recorded more frequent pulmonary embolism cases in the testosterone-treated group. That supports, rather than undermines, the value of routine hematocrit monitoring as part of safe therapy.
Dosage & timing
Typical dose
Not applicable in the sense of drug dosing — what matters here is choosing an injection schedule that minimizes peak concentrations (e.g. more frequent, smaller doses instead of infrequent, large ones) as part of managing erythrocytosis risk.
Form
A blood count assessing hematocrit and hemoglobin — done before starting TRT (baseline value), then periodically throughout therapy.
Testosterone dose and injection frequency directly affect how high peak concentrations run, and it's those peaks — more than the average concentration across a cycle — that correlate most strongly with the severity of erythrocytosis on injectable TRT forms.
Best times to take it
- Measure hematocrit and hemoglobin before starting TRT as a baseline for comparison
- First check usually after 3–4 months of therapy, once the effect on erythropoiesis has had time to show
- Next check around month 12, then typically once a year if values remain stable
- More frequent checks (e.g. every 3 months) with high-erythrocytosis-risk forms (short-acting injections) or after a previously noted hematocrit rise
- An additional check whenever symptoms suggestive of blood hyperviscosity appear (severe headaches, dizziness, facial flushing), regardless of the planned schedule
What actually helps
Reducing the testosterone dose
Strong evidenceThe simplest and often first-line intervention — lowering the dose reduces both average and peak testosterone concentration, proportionally limiting erythropoiesis stimulation. It does require accepting potentially weaker control of hypogonadism symptoms and re-weighing the benefit-risk balance.
Changing the delivery form or injection schedule
Moderate evidenceSwitching from infrequent, large injections (e.g. every 2–3 weeks) to more frequent, smaller doses (e.g. weekly or every few days) flattens the concentration curve and lowers peaks, which studies link to lower erythrocytosis risk. Switching to a transdermal form (gel, patch) gives an even more stable profile and the lowest documented hematocrit-rise risk among available TRT forms.
Therapeutic phlebotomy (blood removal) or blood donation
Early-stage evidenceMechanically removing part of the blood volume directly lowers hematocrit. It's used when values exceed accepted safety thresholds, especially when dose reduction isn't desired or isn't enough. Its long-term effectiveness and safety in the context of clotting risk are, however, debated — some authors point out that repeated blood removal can lead to iron deficiency and paradoxically activate pro-thrombotic pathways, so this approach isn't free of controversy.
Temporarily pausing therapy
Moderate evidenceAt very high hematocrit values, especially with accompanying clinical symptoms (headaches, dizziness) or cardiovascular risk factors, temporarily stopping testosterone until the blood count normalizes is sometimes recommended as a precaution before resuming therapy at a lower dose or in a different form.
Identifying and correcting overlapping factors
Moderate evidenceTreating coexisting sleep apnea, quitting smoking, or avoiding unwarranted iron supplementation limits the additive mechanisms that raise hematocrit independent of testosterone therapy itself, which can allow TRT to continue without needing a dose reduction.
Safety
Side effects & contraindications
Possible side effects
Increased blood viscosity (hyperviscosity) — thicker blood offers more resistance to flow, theoretically increasing the load on the heart and vessels
Elevated, though inconsistent across population RCTs, risk of thromboembolic events (venous thromboembolism, pulmonary embolism) with significantly elevated hematocrit
A possible link to elevated risk of major adverse cardiovascular events (MACE) in the first year of therapy in patients who develop secondary polycythemia
Symptoms tied to excessive blood density at very high values: headaches, dizziness, a feeling of "heavy" blood, and in extreme cases symptoms resembling hyperviscosity syndrome
The need for more frequent blood count checks and potential interventions (dose reduction, phlebotomy), adding to the logistical and financial burden of therapy
Contraindications
Untreated or undiagnosed primary myeloproliferative disease (e.g. polycythemia vera) — TRT can sharply worsen symptoms and clotting risk
Baseline hematocrit above roughly 50% before starting therapy without an explained cause — requires workup before qualifying for TRT, not during it
Untreated, severe obstructive sleep apnea — chronic nocturnal hypoxia on its own raises hematocrit and adds to testosterone's effect
Active or recent venous thromboembolism without an explained and corrected cause
Uncompensated heart failure or significant peripheral vascular disease, where an added rise in blood viscosity carries disproportionately high risk
Interactions
Smoking — on its own raises hematocrit through chronic tissue hypoxia and adds to testosterone's effect
Chronic obstructive pulmonary disease (COPD) and other hypoxic states — intensify erythropoiesis independently of TRT, stacking with the androgen's effect
Exogenous erythropoietin (EPO) or other erythropoiesis-stimulating doping agents — combining with TRT is contraindicated due to a multiplied risk of blood hyperviscosity
Iron supplementation without an indication — with hepcidin already lowered on TRT, this can further ease erythropoiesis in people whose hematocrit is already elevated
High altitude exposure (environmental hypoxia) — the HIF/EPO mechanism overlaps with testosterone's effect, amplifying the hematocrit rise
Dehydration — doesn't increase actual red cell mass, but inflates the measured hematocrit through blood concentration, which can mask or falsely suggest a problem
Is it worth taking?
Who it's for
- Men starting TRT who want to understand why blood count monitoring is a mandatory part of therapy, not a formality
- Patients already on testosterone therapy who've been found to have elevated hematocrit and want to understand the mechanism before deciding on a schedule change
- People choosing a TRT delivery form (injections vs. gel vs. patch) who want to weigh erythrocytosis risk as one of the selection criteria
- Doctors and patients looking for the physiological rationale behind the monitoring schedule and the available intervention options
Not for
- Untreated or undiagnosed primary myeloproliferative disease (e.g. polycythemia vera) — TRT can sharply worsen symptoms and clotting risk
- Baseline hematocrit above roughly 50% before starting therapy without an explained cause — requires workup before qualifying for TRT, not during it
- Untreated, severe obstructive sleep apnea — chronic nocturnal hypoxia on its own raises hematocrit and adds to testosterone's effect
- Active or recent venous thromboembolism without an explained and corrected cause
- Uncompensated heart failure or significant peripheral vascular disease, where an added rise in blood viscosity carries disproportionately high risk
Evidence
Worth knowing
Secondary erythrocytosis is the best and most consistently documented side effect of testosterone therapy among all known TRT effects.
Erythrocytosis risk is described as up to four times higher on TRT than on placebo in randomized trials.
Injectable testosterone forms carry a markedly higher risk of elevated hematocrit than transdermal forms (gels, patches).
Testosterone raises hematocrit through three overlapping pathways: via erythropoietin, directly through the bone marrow, and indirectly by lowering hepcidin, which increases iron availability.
The large TRAVERSE trial confirmed that TRT doesn't significantly increase the overall risk of major cardiovascular events, while also noting more frequent pulmonary embolism cases in the treated group.
Studies
Although elevated hematocrit carries a certain thrombotic risk, evidence for the effectiveness and safety of routine phlebotomy as a way to lower it in testosterone-induced erythrocytosis remains limited — excessive blood removal can paradoxically activate clotting-related pathways through tissue hypoxia and iron deficiency.
Bond P et al., Endocrine Connections, 2024
Testosterone therapy-induced erythrocytosis: can phlebotomy be justified?
Moderate evidenceBond P et al. · Endocrine Connections · 2024
A review critically examining the evidence behind testosterone-induced erythrocytosis and the rationale for phlebotomy as a standard intervention — the authors note that despite a real clotting risk tied to elevated hematocrit, evidence for the effectiveness and safety of routine blood removal is limited, and repeated phlebotomy can paradoxically worsen risk through tissue hypoxia and iron deficiency.
View studySecondary Polycythemia in Men Receiving Testosterone Therapy Increases Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism in the First Year of Therapy
Moderate evidenceOry J et al. · Journal of Urology · 2022
An analysis of a large, multicenter database of TRT patients comparing the risk of major cardiovascular events and venous thromboembolism between men who developed secondary polycythemia (hematocrit ≥52%) and those with normal hematocrit — risk was higher in the polycythemia group during the first year of therapy.
View studyCardiovascular Safety of Testosterone-Replacement Therapy
Strong evidenceLincoff AM et al. · New England Journal of Medicine · 2023
The large randomized TRAVERSE trial assessing the cardiovascular safety of TRT in men with hypogonadism and existing or elevated cardiovascular risk — testosterone proved non-inferior to placebo for major cardiovascular events (MACE), while the treated group showed more frequent pulmonary embolism, atrial fibrillation, and acute kidney injury.
View studySources & bibliography
- Bond et al. 2024 — Endocrine Connections
- Ory et al. 2022 — Journal of Urology
- Lincoff et al. 2023 — TRAVERSE, New England Journal of Medicine
Citations are illustrative for this demo version and require full bibliographic verification by the editorial team before production publication.
Compare with similar entries
About the authors of this entry
Author
dr Piotr ZielińskiEndocrinologist
Piotr reviews content on hormones, metabolic health and supplement pharmacology.
131 publications on this site
Medical review
dr Anna KowalczykEditor-in-Chief, Molecular Biology
Anna oversees the editorial process and scientific review of every publication in the knowledge base. She previously researched autophagy and mitochondrial biology.
50 publications on this site
Related entries
4.7TRT (Testosterone Replacement Therapy) — What Is It and Who Is It For?
TRT isn't a supplement for fatigue — it's pharmacological treatment for a confirmed testosterone deficiency, with a real but limited list of benefits and an equally real list of people who simply don't qualify for it.
4.4TRT — Administration Forms: Injections, Gels, and Patches
Injections, transdermal gels, and patches — the three main forms of testosterone replacement therapy differ in blood-concentration profile, ease of use, and the risk of transferring the hormone to other people.
4.7TRT — Side Effects and Therapy Monitoring
Erythrocytosis, fertility impact, PSA screening, and the cardiovascular risk question — what testosterone replacement therapy safety actually involves and how it's monitored.
4.6Complete Blood Count (CBC)
The most commonly ordered laboratory test in the world — a seemingly simple printout hides information about immunity, oxygen transport, and blood clotting, if you know what to look for.
4.7Hematocrit During TRT — What's a Safe Value, and What to Do If It's Elevated?
50%, 52%, 54%, 56% — each of those numbers on a TRT blood panel means something different. A concrete guide to hematocrit thresholds per the Endocrine Society and AUA guidelines: when more frequent monitoring is enough, when to reduce the dose, when to consider phlebotomy, and when to pause therapy.
4.7How Often to Test Testosterone on TRT? Monitoring Schedule and Checkups
Starting testosterone therapy isn't the end of diagnostics — it's the start of a new, recurring rhythm of checkups. We explain which tests happen at month 3, which at year one, and which need repeating for as long as therapy continues — and how the schedule differs between injectable and gel forms.
4.7What Tests Are Needed Before TRT? The Complete Pre-Treatment Testing List
Before a physician can qualify a patient for testosterone therapy, a far broader panel of tests is needed than testosterone level alone. The full list of blood tests, symptom questionnaires, and criteria that determine whether TRT is safe and appropriate.
4.7TRT and Your Heart — Does Testosterone Therapy Raise Heart Attack Risk?
For a decade, testosterone therapy operated under the shadow of an FDA warning about heart attack risk. The large randomized TRAVERSE trial from 2023 finally gave a clear answer — though not as simple as the headlines suggested. We walk through the whole story, from controversial observational studies to where the evidence stands today.
Related articles
PoradnikiDoes TRT Cause Hair Loss, Acne, and Gynecomastia? Fact vs. Myth
Hair loss, acne, and 'man boobs' are the three most-Googled worries before starting TRT — but none of them is a guaranteed consequence of therapy. We check what physiology and the research actually say about mechanism, dose, and individual susceptibility.
August 15, 2026
PoradnikiTRT and Gynecomastia — Why Does Breast Tissue Grow During Testosterone Therapy?
Gynecomastia on TRT is more than a single sentence in an article about side effects — it's a specific hormonal mechanism you can recognize yourself, track over time, and genuinely treat. A deep guide to aromatization, self-exams, and the real treatment options, from watchful waiting to surgery.
August 15, 2026
PoradnikiTRT and High Estradiol — Symptoms, Causes, and What You Can Do About It
Suspect you have high estradiol on TRT? Before you reach for a forum post and someone else's anastrozole protocol, check which symptoms actually point to it and what order to act in — from bloodwork, through talking to your doctor, to a possible medication.
August 15, 2026
PoradnikiTRT or Lifestyle Change? What Actually Raises Testosterone Before You Consider Therapy
Before considering testosterone replacement therapy, it's worth checking how much sleep, training, and fat loss can realistically achieve — and when these interventions genuinely aren't enough.
July 29, 2026
Comments (2)
- KW
Kasia W. 2 weeks ago
Very clearly explained, especially the interactions section — I hadn't seen it laid out this well anywhere else.
- MT
Marek T. a month ago
Are you planning to update this with the newest study from this year? I saw an interesting meta-analysis.